Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GRAND BRILLIANCE GROUP HOLDINGS LIMITED
君百延集團控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 8372)

CHANGE OF CHAIRMAN OF THE BOARD

The board (the "**Board**") of directors (the "**Directors**") of Grand Brilliance Group Holdings Limited (the "**Company**") hereby announces that with effect from 1 December 2026, (1) Ms. Wong Bik Kwan Bikie ("**Ms. Wong**") will step down from her role as the chairman (the "**Chairman**") of the Board of the Company and remains as an executive Director and chief executive officer of the Company; and (2) Dr. Miu Yin Shun Andrew ("**Dr. Miu**"), the existing non-executive Director, has been appointed as the Chairman of the Company to enhance the corporate governance of the Company. Following the above changes, the Company will comply with code provision C.2.1 of the Corporate Governance Code as set out in the Appendix C1 to the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited ("**GEM Listing Rules**") from 1 December 2026.

The biographical details of Dr. Miu are set out below:

Dr. Miu, aged 59, was appointed as the non-executive Director of the Company on 18 September 2017. He is also a member of the Audit Committee of the Company. Dr. Miu is responsible for providing to the Company consultation on technical information on medical devices.

Dr. Miu obtained a degree of Bachelor of Medicine and Bachelor of Surgery from the Chinese University of Hong Kong in December 1990. He was awarded a fellowship by the Royal College of Surgeons of Edinburgh in July 1995, a fellowship in orthopaedic surgery by the Royal College of Surgeons of Edinburgh in February 2000, a fellowship by the Hong Kong College of Orthopaedic Surgeons in March 2000, a fellowship in orthopaedic surgery by the Hong Kong Academy of Medicine (in orthopaedics) in May 2000, a first fellowship in rehabilitation of the Hong Kong College of Orthopaedic Surgeons in October 2004. He then obtained a degree of Master of Science in Sports Medicine and Health Science from the Chinese University of Hong Kong in November 2015.

Dr. Miu has extensive experience of over 32 years in the medical industry. He is the spouse of Ms. Wong. Dr. Miu is currently an orthopaedic specialist in K&A Orthopaedic & Physiotherapy Centre.

Dr. Miu has entered into an appointment letter for a term of three years commencing from 16 September 2024. He is also subject to retirement by rotation and re-election at least once every three years according to the articles of association of the Company, the GEM Listing Rules and other applicable laws. Dr. Miu is entitled to a remuneration of HK$120,000 per annum which remains unchanged following his appointment as the Chairman. The remuneration package of Dr. Miu was determined with reference to his duties, responsibilities as well as the Company's remuneration policy and the prevailing market conditions, and will be reviewed by the Board on an annual basis.

As at the date of this announcement, Dr. Miu holds 568,968,001 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO") of which 568,028,001 shares were held by a controlled corporation owned by Ms. Wong, the spouse of Dr. Miu, and 940,000 shares were held by Ms. Wong and Dr. Miu jointly and directly.

Save as disclosed herein, to the best knowledge of the Directors, as at the date of this announcement, Dr. Miu (i) does not have any other relationship with any Director, senior management, substantial or controlling shareholder (as defined in the GEM Listing Rules) of the Company; (ii) does not have any other interest in the securities of the Company or any of its associated corporations within the meaning of Part XV of the SFO; and (iii) does not hold any other position within the Group. Save as disclosed herein, there is no other matter relating to the appointment of Dr. Miu as the Chairman that needs to be brought to the attention of the holders of securities of the Company, nor is there any information as required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board would like to take this opportunity to welcome Dr. Miu on his appointment as the Chairman of the Company.

By order of the Board
Grand Brilliance Group Holdings Limited
Wong Bik Kwan Bikie
Executive Director and Chief Executive Officer

Hong Kong, 23 November 2026

As at the date of this announcement, the executive Director is Ms. Wong Bik Kwan Bikie; the non-executive Directors are Dr. Miu Yin Shun Andrew and Mr. Chiu Man Wai; and the independent non-executive Directors are Mr. Ng Leung Sing SBS, JP, Mr. Chow Ming Po Aaron and Mr. Chiu Fan Wa.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the ''Latest Listed Company Announcements'' page of the website of Stock Exchange (www.hkexnews.hk) for at least seven days from the date of its publication and the website of the Company (www.grandbrilliancegroup.com).